Topic: Coronavirus

Latest content

Pfizer in crosshairs once again in latest covid-19-related patent suit

Enanta Pharmaceuticals is seeking a share of blockbuster antiviral revenues

24 June 2022

Covid impact on US patent filings is now becoming clearer

Data on law firms ranked by 2021 grants shows a slide that may link to filing strategies changing because of pandemic-induced budget cuts

17 June 2022

Breaking: Vaccine IP waiver agreed by WTO members

The agreed IP waiver is less far-reaching than the original proposal, but underscores how the pandemic has impacted IP politics.

17 June 2022

New IP finance play, Ukraine tribute, patent litigation trends and plenty more as IPBC Global 2022 comes to an end

Despite the close attentions of a tornado and the deadening heatwave that preceded and followed it, delegates and speakers in Chicago were in good form for the final day of this year's event

15 June 2022

No turning back the clock on pandemic changes, says EPO Boards of Appeal president

BoA President Carl Josefsson also tells IAM that backlog reduction efforts are on track and the organisation is turning its attention toward timeliness of proceedings

27 May 2022

Moderna says US government on the hook to pay any royalties due to mRNA patent owners

The company claims any infringing uses of its vaccine are insulated from liability under compulsory licensing law

17 May 2022

A fairer way to determine royalties in Turkish compulsory licensing

If compulsory licensing is used in Turkey, it is imperative that the individual requirements of each case are considered. This is especially important when it comes to facilitating access to medical treatments for covid-19.

30 March 2022

Fight for covid-19 revenues triggers wave of new mRNA lawsuits

Several new legal actions have been launched by lipid nanoparticle technology owners

28 March 2022

Breakthrough in TRIPS covid waiver negotiations – here’s what you need to know

There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation

16 March 2022

Vaccine hub leader welcomes new Moderna patent pledge, but calls for collaboration

Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment

14 March 2022

Get unlimited access to all IAM content